Humira buyers appeal AbbVie ruling to Seventh Circuit
31-07-2020
Clean sweep for AbbVie in Humira litigation
15-05-2019
AbbVie and Pfizer in Humira licensing deal
03-12-2018
AbbVie secures another Humira settlement
12-10-2018
04-04-2019
casimiropt / Shutterstock.com
AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira (adalimumab).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, antitrust, competition, licensing deals, patent thickets, Pfizer, Sandoz, Mylan, biosimilars